Viyash Scientific to acquire Italy’s BioForLife for Rs. 188 crore
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Subscribe To Our Newsletter & Stay Updated